Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
First Patient Dosed in Beckley Psytech’s Phase 2a Study for Treatment Resistant Depression
Beckley Psytech, a major private psychedelic medicine firm, has moved its Phase 2 study forward and begun dosing patients for Treatment-Resistant Depression.
BPL-003 is Beckley Psytech’s formulation of 5-MeO-DMT and the clinical trial will explore the effects of a single dose of BPL-003 in patients with Treatment-Resistant Depression (TRD)
Topline results are expected in 2023 and will be used alongside data from Beckley Psytech’s global multi-site Phase IIb study of BPL-003 in patients with TRD to inform the future clinical development of BPL-003.
Albert Labs Receives Acceptance of 35 Patent Claims for Manufacturing Technology
Albert Labs has received preliminary acceptance of 35 novel inventive claims as part of its published International PCT Patent Application (No. PCT/CA2022/051281).
The Company’s proprietary manufacturing methodology, developed and validated in-house at Albert Labs’ Vancouver facility, facilitates the production and scaling of highly potent yields of its KRN Active Pharmaceutical Ingredient (API).
This protected technology provides industry-leading outputs of psilocybin, with sixteen times the amount of psilocybin per mass unit of mycelia. It also ensures standardization, consistency, and a reduced risk of contamination from research to commercial GMP production levels.
American Medical Association to Issue First Code for Psychedelic Therapies to COMPASS and MAPS
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved.
“This is a major step forward to enabling broad and equitable access to psychedelic therapies,” said Kabir Nath, CEO, COMPASS Pathways. “This collaboration with MAPS PBC to develop a new CPT code aims to ensure that psychedelic therapies, if approved, could be integrated into healthcare systems, reimbursed by payers, and made available to the people who need them.”
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
Optimi Health announced that it has entered into a CAD$1.2 million definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research and clinical trials.
Bill Ciprick, Optimi’s CEO, said, “This is a big day for Optimi. To be selected as the singular supply entity in the sector capable of scaling to help fulfill the needs of our Client reflects our ability to deliver substantial value to the research community and our shareholders.”
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
